Kulikov A.Y. 6198

Pharmacoeconomic evaluation of axitinib introduction in metastatic renal cell carcinoma treatment scheme

During the pharmacoeconomic analysis of axitinib use as a secondline therapy for mRCC, it was found that this target therapy regimen would significantly increase the time to progression, overall survival and annual survival rate. Despite the high cost of this treatment regimen at the horizon of ten year study, the treatment regimen including axitinib characterized by the lowest values of the cost-effectiveness ratio, reflecting the costs incurred by the health care system for patient’s life saving, and increme
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF